523 related articles for article (PubMed ID: 15867230)
21. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature.
Hornreich G; Beller U; Lavie O; Renbaum P; Cohen Y; Levy-Lahad E
Gynecol Oncol; 1999 Nov; 75(2):300-4. PubMed ID: 10525392
[TBL] [Abstract][Full Text] [Related]
22. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.
Sobel G; Németh J; Kiss A; Lotz G; Szabó I; Udvarhelyi N; Schaff Z; Páska C
Gynecol Oncol; 2006 Nov; 103(2):591-8. PubMed ID: 16797678
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
Tassi RA; Bignotti E; Rossi E; Falchetti M; Donzelli C; Calza S; Ravaggi A; Bandiera E; Pecorelli S; Santin AD
Gynecol Oncol; 2007 Jun; 105(3):578-85. PubMed ID: 17343903
[TBL] [Abstract][Full Text] [Related]
24. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
25. GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma.
Idrees MT; Schlosshauer P; Li G; Burstein DE
Histopathology; 2006 Jul; 49(1):75-81. PubMed ID: 16842248
[TBL] [Abstract][Full Text] [Related]
26. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features.
Bartosch C; Manuel Lopes J; Oliva E
Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268
[TBL] [Abstract][Full Text] [Related]
27. [Uterine papillary serous carcinoma--a different kind of tumor].
Steinman N; Avni A
Harefuah; 1999 May; 136(10):810-2. PubMed ID: 10955120
[No Abstract] [Full Text] [Related]
28. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
[TBL] [Abstract][Full Text] [Related]
29. Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.
Shih IeM; Wang TL
J Pathol; 2011 May; 224(1):1-4. PubMed ID: 21432855
[TBL] [Abstract][Full Text] [Related]
30. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
31. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
[TBL] [Abstract][Full Text] [Related]
32. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
33. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
34. BRCA2 germline mutation in a woman with uterine serous papillary carcinoma--case report.
Lavie O; Ben-Arie A; Pilip A; Rennert G; Cohen Y; Feiner B; Auslnader R
Gynecol Oncol; 2005 Nov; 99(2):486-8. PubMed ID: 16051327
[TBL] [Abstract][Full Text] [Related]
35. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
36. Haptoglobin expression in endometrioid adenocarcinoma of the uterus.
Nabli H; Tuller E; Sharpe-Timms KL
Reprod Sci; 2010 Jan; 17(1):47-55. PubMed ID: 19801537
[TBL] [Abstract][Full Text] [Related]
37. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
Dong Y; Kaushal A; Bui L; Chu S; Fuller PJ; Nicklin J; Samaratunga H; Clements JA
Clin Cancer Res; 2001 Aug; 7(8):2363-71. PubMed ID: 11489814
[TBL] [Abstract][Full Text] [Related]
38. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
39. Methylation profiles of endometrioid and serous endometrial cancers.
Seeber LM; Zweemer RP; Marchionni L; Massuger LF; Smit VT; van Baal WM; Verheijen RH; van Diest PJ
Endocr Relat Cancer; 2010 Sep; 17(3):663-73. PubMed ID: 20488783
[TBL] [Abstract][Full Text] [Related]
40. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
